1.1Uncapped bacterial ribosome entry
The leader contains a ribosome-binding sequence upstream of the start codon. Base pairing with the small-subunit ribosomal RNA positions the start codon for initiation.
Generated automatically. Not reviewed by a person. Not legal advice or an opinion.
Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.
The leader contains a ribosome-binding sequence upstream of the start codon. Base pairing with the small-subunit ribosomal RNA positions the start codon for initiation.
Complementary segments near the 3′ end fold into a stem with a short loop. A stem-loop-binding protein recognizes the folded end and supports translation in a cell-free extract containing the corresponding initiation factors.
A uridine-rich region and a short adenosine-rich segment within the transcript form stacked base triples near the 3′ terminus. The folded structure reduces access to the end by 3′ exonucleases.
The cap retains its 7-methylguanosine and 5′–5′ triphosphate linkage. Methylating the first transcribed nucleotide at the ribose 2′ oxygen reduces binding by a cap-sensitive RNA recognition protein.
A DNA template encodes the number of terminal adenosines in the transcript. A longer continuous adenosine tract provides room for more polyadenosine-binding protein molecules, which interact with translation initiation factors.
Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.
A noncoding reference RNA carries a 5′ trimethylguanosine cap in place of a 7-methylguanosine cap. Its 3′ poly(A) tail carries deuterium on ribose carbon atoms. Capillary electrophoresis compares its migration with that of a reference carrying the 7-methylguanosine cap on the same RNA sequence and isotope-labeled tail.
Three noncoding RNA references share a 60-nucleotide body and a 5′ cap bearing deuterium on a carbon atom. Their 3′ poly(A) tails contain 15, 30, and 60 adenosine residues. Denaturing capillary electrophoresis measures each reference separately, and the measured migration times form a calibration series for the three total RNA lengths.
Two noncoding RNA standards share the same sequence, 5′ cap structure, and 3′ poly(A) length. One standard carries carbon-bound deuterium in the cap, and the other carries protium at the same positions. Mixtures contain 0, 25, 50, 75, and 100 mol% of the deuterated standard at a fixed total RNA concentration. Mass spectrometry measures both forms, and their integrated signal fractions are plotted against the prepared mole fractions.
A microfluidic RNA extraction cartridge contains a silica capture chamber between its sample inlet and eluate outlet. The input sample contains a known amount of noncoding reference RNA with a 5′ cap and a deuterium-labeled 3′ poly(A) tail. Mass spectrometry measures the labeled reference in the eluate, and the ratio of the recovered amount to the input amount gives the recovery fraction.
A noncoding RNA reference has a 5′ cap, a 3′ poly(A) tail, and carbon-bound deuterium at one of the two termini. A mass spectrometer records tandem spectra for terminal fragments whose compositions are known. Software matches the observed isotope envelopes against calculated envelopes for the capped 5′ fragment and the polyadenylated 3′ fragment, then reports which fragment carries the label and the mass error for each assignment.
A 7-methylguanosine cap attaches to the first transcribed nucleotide through a 5′–5′ triphosphate linkage. A homopolymeric region in the DNA template encodes a 3′ tail of 60 adenosines.
The cap contains a 7-methylguanosine whose N7 methyl group is CD₃. The three deuterium atoms occupy carbon-bound positions on the cap methyl group.
The 3′ poly(A) tail includes adenosine residues with deuterium at carbon 8 of the adenine ring. The residues retain the ribose and the 3′–5′ phosphodiester linkages of the tail.
Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.
In some embodiments, a provided mRNA comprises a 5′-UTR sequence, a 5′ cap, a coding region, a 3′-UTR sequence and a poly-A tail.A · US 2016/0031928 A1 · ¶ 42
A poly A tail was added to the 3′ end of the oligonucleotide sequence, and a tailing reaction system was prepared according to each reagent and its addition amount in Table 1.B · US 11,597,922 B2 · ¶ 45
An empty cell means only that no passage was reproduced there.
In particular, poor stability of mRNAs used in gene replacement therapy can result in insufficient or less optimal production of the encoded therapeutic protein in vivo.A · US 2016/0031928 A1 · ¶ 5
The present invention provides an improved modified mRNA for more stable, robust and sustained in vivo protein production.A · US 2016/0031928 A1 · ¶ 6
Since antisense DNA is an artificially synthesized sequence, there are base insertions and deletions during the synthesis process, resulting in a large amount of impurities in the synthesized DNA, and the synthesized sequence needs to be purified for pharmaceutical use, so it is necessary to analyze and confirm the purified sequence components.B · US 11,597,922 B2 · ¶ 8
However, there is currently no good solution for the analysis of single-stranded oligonucleotide sequences.B · US 11,597,922 B2 · ¶ 8
patent.fyi, US 2026/0356876 A1, claim 1, first published 2026-11-20T08:11:50-05:00, https://patent.fyi/US20260356876/, SHA-256 1f98bd34d2e1b206ab04c41f6687c609bd1ce767bcb0795fd317cf9c44254deb